| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Depart,ment of Integrative Pharmacology, GI Biology, AstraZeneca R&D Molndal, Molndal, Sweden
* To whom correspondence should be addressed. E-mail: silvia.melgar{at}astrazeneca.com.
Exposure to dextran sulphate sodium (DSS) induces acute colitis, which is normally
resolved after DSS removal. To study chronicity, mice are typically subjected to 3-5
cycles of weekly DSS-exposures, each followed by resting period of 1-2 weeks.
Herein, we describe a novel and convenient way of inducing chronic, progressive
colitis by a single exposure to DSS. C57BL/6 mice exposed to DSS for 5 days,
developed acute colitis that progressed into severe chronic inflammation. The plasma
haptoglobin levels remained high during the chronic phase, showing that the
inflammation was active. Surprisingly, the mice regained their original weight along
with the progression of colitis and the only apparent symptom was loose feces.
Histopathological changes 4 weeks after DSS removal were dense infiltrates of
mononuclear cells, irregular epithelial structure and persistent deposits of collagen. A
progressive production of the cytokines IL-1
, IL-12p70 and IL-17 correlated to the
extensive cellular infiltration, whereas high IFN-
production was mainly found late
in the chronic phase. Similar to C57BL/6, BALB/c mice exposed to five days of DSS
developed acute colitis as previously described. The acute colitis was accompanied by
elevated plasma levels of haptoglobin and increased colonic levels of IL-1
/, IL-6,
IL-18 and G-CSF. However, soon after DSS-removal BALB/c mice recovered and
were symptom-free within two weeks and completely recovered 4 weeks after DSS
removal in terms of histopathology, haptoglobin levels and local cytokine production.
In summary, these data stress the effect of genetic background on the outcome of
DSS-provocation. We believe that the current protocol to induce chronic colitis in
C57BL/6 offers a robust model for validating future therapies for treatment of
inflammatory bowel disease.
This article has been cited by other articles:
|
|
 |
|
  Z. Ye, Z. Liu, A. Henderson, K. Lee, J. Hostetter, M. Wannemuehler, and S. Hendrich Increased CYP4B1 mRNA Is Associated with the Inhibition of Dextran Sulfate Sodium-Induced Colitis by Caffeic Acid in Mice Experimental Biology and Medicine, June 1, 2009; 234(6): 605 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Snook, P. Li, B. J. Stafford, E. J. Faul, L. Huang, R. C. Birbe, A. Bombonati, S. Schulz, M. J. Schnell, L. C. Eisenlohr, et al. Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease Cancer Res., April 15, 2009; 69(8): 3537 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Schwartz, M. Abolhassani, M. Pooya, J.-M. Steyaert, X. Wertz, M. Israel, A. Guais, and P. Chaumet-Riffaud Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A Am J Physiol Gastrointest Liver Physiol, November 1, 2008; 295(5): G934 - G941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Turovskaya, D. Foell, P. Sinha, T. Vogl, R. Newlin, J. Nayak, M. Nguyen, A. Olsson, P. P. Nawroth, A. Bierhaus, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis Carcinogenesis, October 1, 2008; 29(10): 2035 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Swee, C. L. Wilson, Y. Wang, J. K. McGuire, and W. C. Parks Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients J. Leukoc. Biol., June 1, 2008; 83(6): 1404 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Horino, M. Fujimoto, F. Terabe, S. Serada, T. Takahashi, Y. Soma, K. Tanaka, T. Chinen, A. Yoshimura, S. Nomura, et al. Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice Int. Immunol., June 1, 2008; 20(6): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Jia, J. R. Lupton, R. Smith, B. R. Weeks, E. Callaway, L. A. Davidson, W. Kim, Y.-Y. Fan, P. Yang, R. A. Newman, et al. Reduced Colitis-Associated Colon Cancer in Fat-1 (n-3 Fatty Acid Desaturase) Transgenic Mice Cancer Res., May 15, 2008; 68(10): 3985 - 3991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. O. Yang, S. H. Chang, H. Park, R. Nurieva, B. Shah, L. Acero, Y.-H. Wang, K. S. Schluns, R. R. Broaddus, Z. Zhu, et al. Regulation of inflammatory responses by IL-17F J. Exp. Med., May 12, 2008; 205(5): 1063 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Melgar, M. Bjursell, A.-K. Gerdin, L. Svensson, E. Michaelsson, and M. Bohlooly-Y Mice with experimental colitis show an altered metabolism with decreased metabolic rate Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G165 - G172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Okada, Y Tsuzuki, J Miyazaki, K Matsuzaki, R Hokari, S Komoto, S Kato, A Kawaguchi, S Nagao, K Itoh, et al. Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing Gut, May 1, 2006; 55(5): 681 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Ortega-Cava, S. Ishihara, M. A. K. Rumi, M. M. Aziz, H. Kazumori, T. Yuki, Y. Mishima, I. Moriyama, C. Kadota, N. Oshima, et al. Epithelial Toll-Like Receptor 5 Is Constitutively Localized in the Mouse Cecum and Exhibits Distinctive Down-Regulation during Experimental Colitis Clin. Vaccine Immunol., January 1, 2006; 13(1): 132 - 138. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
